Long-acting PTH Compound Intermittent Dosing for BMD Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for bone mineral density (BMD) abnormalities, particularly in patients with increased BMD due to hypoparathyroidism, fail to effectively normalize BMD and maintain serum calcium levels, leading to ongoing bone density issues and potential adverse effects.

Innovation Solution

A long-acting PTH compound is administered, which initially increases bone turnover markers, subsequently normalizing BMD by stabilizing these markers and adjusting doses to maintain normal serum calcium levels, effectively reducing BMD in trabecular bones while avoiding cortical bone loss.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If daily injections of PTH(1-84) are administered to treat hypoparathyroidism, then serum calcium levels are controlled, but bone mineral density increases excessively

Engineering Contradiction:

Improveserum calcium controlVSAvoidbone mineral density increase

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent employs intermittent dosing of PTH(1-84) where treatment is administered for limited periods (e.g., 2-3 months) followed by breaks, rather than continuous daily injection. This periodic administration pattern allows bone density to stabilize or decrease between treatment cycles while maintaining serum calcium control during active treatment phases, thereby resolving the contradiction between reliable calcium control and excessive bone density increase

Inventive Principle:

Principle #19Periodic action

2Reliability

If prolonged therapy with PTH(1-84) is used, then serum calcium control is maintained, but cortical bone loss occurs

Engineering Contradiction:

Improveserum calcium controlVSAvoidcortical bone loss

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

By implementing intermittent treatment cycles with break periods, the patent reduces cumulative exposure to PTH(1-84) while maintaining adequate calcium control during active phases. This periodic approach allows cortical bone to recover or stabilize between cycles, preventing the progressive cortical bone loss associated with prolonged continuous therapy

Inventive Principle:

Principle #19Periodic action

3Reliability

If higher doses of PTH compound are administered, then serum calcium levels are maintained, but bone turnover increases excessively

Engineering Contradiction:

Improveserum calcium maintenanceVSAvoidbone turnover rate

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The intermittent dosing strategy allows bone turnover markers to decrease during treatment-free intervals while serum calcium remains controlled during active treatment. This periodic modulation prevents sustained high bone turnover that would occur with continuous higher dosing, resolving the contradiction between maintaining calcium levels and controlling bone turnover rate

Inventive Principle:

Principle #19Periodic action

Data Source

PatentUS20240382567A1Long-acting PTH compound treatments

Publication Date: 2024.11.21 ASCENDIS PHARMA BONE DISEASES AS

AI summary

The present invention relates to a long-acting PTH compound for use in the reduction of bone mineral density (BMD) in a patient having an increased BMD and to a particular dosage regimen of such long-acting PTH compound and other related aspects.